Study of humoral and cellular immunity in vaccinated with mRNA-1273. 2022

Juan Francisco Gutiérrez-Bautista, and Miguel Ángel López-Nevot, and Esther Gómez-Vicente, and Trinidad Quesada, and Eva María Marín, and Ana Rodríguez, and Ana Isabel Rodríguez, and Javier Rodríguez-Granger, and Fernando Cobo, and Antonio Sampedro
Departamento de Bioquímica, Biología Molecular III e Inmunología, University of Granada, Granada, Spain.

The new vaccines against SARS-CoV-2 have raised a lot of expectations about their ability to induce immunity and the duration of this. This is the case of mRNA vaccines such as Moderna's mRNA-1273. Therefore, it is necessary to study the humoral and cellular immunity generated by these vaccines. Our objectives are determining what is the normal response of antibody production, and what is the level of protective antibodies and monitoring patients in case of subsequent infection with COVID-19. We present the first results of a longitudinal study of the humoral response in 601 health workers vaccinated with Moderna. The results show a humoral immunity at 90 days after the second dose of 100%, with a strong decrease between the levels of circulating anti-S IgG antibodies between days 30 and 90 post-vaccination. Observing a steeper decline in those who had higher titles at the beginning. In addition, we present a cellular response of 86% at three months after the second dose, which is related to low humoral response.

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D008137 Longitudinal Studies Studies in which variables relating to an individual or group of individuals are assessed over a period of time. Bogalusa Heart Study,California Teachers Study,Framingham Heart Study,Jackson Heart Study,Longitudinal Survey,Tuskegee Syphilis Study,Bogalusa Heart Studies,California Teachers Studies,Framingham Heart Studies,Heart Studies, Bogalusa,Heart Studies, Framingham,Heart Studies, Jackson,Heart Study, Bogalusa,Heart Study, Framingham,Heart Study, Jackson,Jackson Heart Studies,Longitudinal Study,Longitudinal Surveys,Studies, Bogalusa Heart,Studies, California Teachers,Studies, Jackson Heart,Studies, Longitudinal,Study, Bogalusa Heart,Study, California Teachers,Study, Longitudinal,Survey, Longitudinal,Surveys, Longitudinal,Syphilis Studies, Tuskegee,Syphilis Study, Tuskegee,Teachers Studies, California,Teachers Study, California,Tuskegee Syphilis Studies
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D000086663 COVID-19 Vaccines Vaccines or candidate vaccines containing SARS-CoV-2 component antigens, genetic materials, or inactivated SARS-CoV-2 virus, and designed to prevent COVID-19. 2019 Novel Coronavirus Vaccine,2019 Novel Coronavirus Vaccines,2019-nCoV Vaccine,2019-nCoV Vaccines,COVID 19 Vaccine,COVID-19 Vaccine,COVID-19 Virus Vaccine,COVID-19 Virus Vaccines,COVID19 Vaccine,COVID19 Vaccines,COVID19 Virus Vaccine,COVID19 Virus Vaccines,Coronavirus Disease 2019 Vaccine,Coronavirus Disease 2019 Vaccines,Coronavirus Disease 2019 Virus Vaccine,Coronavirus Disease 2019 Virus Vaccines,Coronavirus Disease-19 Vaccine,Coronavirus Disease-19 Vaccines,SARS Coronavirus 2 Vaccines,SARS-CoV-2 Vaccine,SARS-CoV-2 Vaccines,SARS2 Vaccine,SARS2 Vaccines,2019 nCoV Vaccine,2019 nCoV Vaccines,COVID 19 Vaccines,COVID 19 Virus Vaccine,COVID 19 Virus Vaccines,Coronavirus Disease 19 Vaccine,Coronavirus Disease 19 Vaccines,SARS CoV 2 Vaccine,SARS CoV 2 Vaccines,Vaccine, 2019-nCoV,Vaccine, COVID 19,Vaccine, COVID-19,Vaccine, COVID-19 Virus,Vaccine, COVID19,Vaccine, COVID19 Virus,Vaccine, Coronavirus Disease-19,Vaccine, SARS-CoV-2,Vaccine, SARS2,Vaccines, 2019-nCoV,Vaccines, COVID-19,Vaccines, COVID-19 Virus,Vaccines, COVID19,Vaccines, COVID19 Virus,Vaccines, Coronavirus Disease-19,Vaccines, SARS-CoV-2,Vaccines, SARS2,Virus Vaccine, COVID-19,Virus Vaccine, COVID19,Virus Vaccines, COVID-19,Virus Vaccines, COVID19
D000090982 BNT162 Vaccine mRNA vaccine against SARS-CoV-2 developed by Pfizer and BioNTech. Abdavomeran,BNT-162A1,BNT-162B1,BNT-162B2,BNT-162C2,BNT162A1,BNT162B1,BNT162B2,BNT162C2,COVID-19 Vaccine Pfizer-BioNTech,Comirnaty,Pfizer Covid-19 Vaccine,Pidacmeran,Tozinameran,BNT 162A1,BNT 162B1,BNT 162B2,BNT 162C2,COVID 19 Vaccine Pfizer BioNTech,Covid-19 Vaccine, Pfizer,Pfizer Covid 19 Vaccine,Pfizer-BioNTech, COVID-19 Vaccine,Vaccine Pfizer-BioNTech, COVID-19,Vaccine, BNT162,Vaccine, Pfizer Covid-19
D000090983 2019-nCoV Vaccine mRNA-1273 mRNA vaccine against SARS-CoV-2, developed by Moderna. COVID-19 Vaccine Moderna,CX-024414,Elasomeran,M-1273,Moderna COVID-19 Vaccine,Moderna COVID-19 Vaccine RNA,Moderna COVID-19 Vaccine, Bivalent,Spikevax,TAK-919,mRNA-1273,mRNA-1273.211,2019 nCoV Vaccine mRNA 1273,COVID 19 Vaccine Moderna,COVID-19 Vaccine, Moderna,CX 024414,CX024414,M 1273,M1273,Moderna COVID 19 Vaccine,Moderna COVID 19 Vaccine RNA,Moderna COVID 19 Vaccine, Bivalent,Moderna, COVID-19 Vaccine,TAK 919,TAK919,Vaccine, Moderna COVID-19,mRNA 1273,mRNA 1273.211,mRNA-1273, 2019-nCoV Vaccine
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D014612 Vaccines Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases. Vaccine

Related Publications

Juan Francisco Gutiérrez-Bautista, and Miguel Ángel López-Nevot, and Esther Gómez-Vicente, and Trinidad Quesada, and Eva María Marín, and Ana Rodríguez, and Ana Isabel Rodríguez, and Javier Rodríguez-Granger, and Fernando Cobo, and Antonio Sampedro
June 1977, Revista brasileira de pesquisas medicas e biologicas,
Juan Francisco Gutiérrez-Bautista, and Miguel Ángel López-Nevot, and Esther Gómez-Vicente, and Trinidad Quesada, and Eva María Marín, and Ana Rodríguez, and Ana Isabel Rodríguez, and Javier Rodríguez-Granger, and Fernando Cobo, and Antonio Sampedro
February 2023, Life (Basel, Switzerland),
Juan Francisco Gutiérrez-Bautista, and Miguel Ángel López-Nevot, and Esther Gómez-Vicente, and Trinidad Quesada, and Eva María Marín, and Ana Rodríguez, and Ana Isabel Rodríguez, and Javier Rodríguez-Granger, and Fernando Cobo, and Antonio Sampedro
October 2021, The Lancet regional health. Europe,
Juan Francisco Gutiérrez-Bautista, and Miguel Ángel López-Nevot, and Esther Gómez-Vicente, and Trinidad Quesada, and Eva María Marín, and Ana Rodríguez, and Ana Isabel Rodríguez, and Javier Rodríguez-Granger, and Fernando Cobo, and Antonio Sampedro
February 2022, Blood advances,
Juan Francisco Gutiérrez-Bautista, and Miguel Ángel López-Nevot, and Esther Gómez-Vicente, and Trinidad Quesada, and Eva María Marín, and Ana Rodríguez, and Ana Isabel Rodríguez, and Javier Rodríguez-Granger, and Fernando Cobo, and Antonio Sampedro
September 2021, Cancer cell,
Juan Francisco Gutiérrez-Bautista, and Miguel Ángel López-Nevot, and Esther Gómez-Vicente, and Trinidad Quesada, and Eva María Marín, and Ana Rodríguez, and Ana Isabel Rodríguez, and Javier Rodríguez-Granger, and Fernando Cobo, and Antonio Sampedro
May 1982, Clinical and experimental immunology,
Juan Francisco Gutiérrez-Bautista, and Miguel Ángel López-Nevot, and Esther Gómez-Vicente, and Trinidad Quesada, and Eva María Marín, and Ana Rodríguez, and Ana Isabel Rodríguez, and Javier Rodríguez-Granger, and Fernando Cobo, and Antonio Sampedro
December 2022, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology,
Juan Francisco Gutiérrez-Bautista, and Miguel Ángel López-Nevot, and Esther Gómez-Vicente, and Trinidad Quesada, and Eva María Marín, and Ana Rodríguez, and Ana Isabel Rodríguez, and Javier Rodríguez-Granger, and Fernando Cobo, and Antonio Sampedro
August 2021, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,
Juan Francisco Gutiérrez-Bautista, and Miguel Ángel López-Nevot, and Esther Gómez-Vicente, and Trinidad Quesada, and Eva María Marín, and Ana Rodríguez, and Ana Isabel Rodríguez, and Javier Rodríguez-Granger, and Fernando Cobo, and Antonio Sampedro
November 2021, The Lancet regional health. Europe,
Juan Francisco Gutiérrez-Bautista, and Miguel Ángel López-Nevot, and Esther Gómez-Vicente, and Trinidad Quesada, and Eva María Marín, and Ana Rodríguez, and Ana Isabel Rodríguez, and Javier Rodríguez-Granger, and Fernando Cobo, and Antonio Sampedro
December 2021, Kidney international,
Copied contents to your clipboard!